Author(s)

Babacar Niang^1*, Lamine Thiam², Fatou Ly³, Indou Dème Ly¹, Djibril Boiro⁴, Amadou Sow⁴, Aliou Thiongane¹, Aliou Abdoulaye Ndongo⁵, Aminata Mbaye¹, Younoussa Keita⁵, Abou Ba¹, Idrissa Demba Ba¹, Yaay Joor Dieng¹, Dienaba Fafa Cissé³, Papa Matar Faye¹, Amadou Lamine Fall¹, Ousmane Ndiaye¹

¹Albert Royer National Children Hospital Center, Dakar, Senegal.
²La Paix Hospital, Ziguinchor, Senegal.
³Pediatric Ward, University Hospital Center of Pikine, Dakar, Senegal.
⁴Pediatric Ward, University Hospital Center of Abass Ndao, Dakar, Senegal.
⁵Pediatric Ward, University Hospital Center of Aristide Le Dantec, Dakar, Senegal.

Graves’ disease is the most common cause of hyperthyroidism. Adequate management is an area of controversy, especially when it comes to children. The objective of our study was to assess the outcome of Graves’ disease treatment in Albert Royer Children Hospital of Dakar. This was a retrospective study conducted from 2001 to 2015, and which involved all children between 0 to 15 years of age who were being monitored in the Albert Royer National Children Hospital. The evolutionary modalities were: stability, remission, failure, relapse, lost to follow-up and death. The data were analyzed with SPSS software version 20.0. For the comparisons, the KHI 2 or Fisher test was used with a significance threshold (p < 0.05). During the study period, 88 children were enrolled. The average age was 8.6 years [ranging from 8 months to 15 years]. The consultation delay was 11.36 months. In our study, 61.4% of the patients were regular in the follow-up, the observance was good in 40.9% of the cases and 19 patients (21.6%) were lost to follow-up. Clinical courses of 69 children after treatment with Carbimazole for 37 months were promising in 21 cases (30.43%), with 17 cases of remission (24.63%) and 4 cases of stability (5.8%). Age older than 10, the initial ATD dose greater than 1 mg/kg/day and the initial free T4 lower than 50 pmol/l were significantly associated with remission with a p value of 0.01; 0.024 and 0.004.

Graves’ Disease, Child, Antithyroid Drug, Remission, Senegal

Niang, B. , Thiam, L. , Ly, F. , Ly, I. , Boiro, D. , Sow, A. , Thiongane, A. , Ndongo, A. , Mbaye, A. , Keita, Y. , Ba, A. , Ba, I. , Dieng, Y. , Cissé, D. , Faye, P. , Fall, A. and Ndiaye, O. (2019) Evolutionary Profile of Graves’ Disease in Children at Albert Royer National Children Hospital in Dakar. Open Journal of Pediatrics, 9, 119-125. doi: 10.4236/ojped.2019.92012.